When a group of device CEOs first assembled in Phoenix last October for a two-day conference, 55% cited FDA regulatory hurdles as the most pressing issue facing their companies; 15% cited the influence of managed care. By the second day, following several panels discussing the changing dynamics of the device marketplace, the number citing regulatory hurdles had dropped to 43%. Even more executives, 45%, were by then citing cost containment pressures driven by managed care and capitation as having the biggest impact on the medical device industry (See Figures 1 and 2).
Although the respondents provided their answers to slightly different questions on each day, the shift in judgment regarding the impact...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?